A new report on the generalized myasthenia gravis (gMG) market projects growth through 2034. The main drivers are increased diagnosis rates and the launch of new therapies. The US currently holds the largest market share compared to the EU, UK, and Japan. Key companies highlighted in the pipeline include Novartis, Cartesian Therapeutics, and Dianthus Therapeutics. Their late-stage assets (FABHALTA, Descartes-08, and Claseprubart) are expected to shift treatment options away from standard steroids toward targeted biologics and CAR-T therapies. Argenx and J&J are also mentioned for their active roles in the space.